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Abstract 
Substantial progress has been made in our understanding of the pathogenetic basis of myeloproliferative 
neoplasms. The discovery of mutations in JAK2 over a decade ago heralded a new age for patient care as a 
consequence of improved diagnosis and the development of therapeutic JAK inhibitors. The more recent 
identification of mutations in calreticulin brought with it a sense of completeness, with the vast majority of 
MPN patients now having a biological basis for their excessive myeloproliferation. We are also beginning to 
understand the processes that lead to acquisition of somatic mutations, and the factors that influence 
subsequent clonal expansion and emergence of disease. Extended genomic profiling has established a 
multitude of additional acquired mutations, particularly prevalent in MF where their presence carries 
prognostic implications. A major goal is to integrate genetic, clinical and laboratory features to identify 
patients that share disease biology and clinical outcome such that therapies, both existing and novel, can be 
better targeted. 
 
Learning objectives 
-To understand the central role of aberrant JAK-STAT signaling in driving the myeloproliferative phenotype.  
-To appreciate the factors that may influence the earliest stages of MPN emergence. 
-To become familiar with the range of additional mutations in MPNs and their role in disease biology.  
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Introduction 
The myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders characterized, in 
chronic phase, by an overproduction of differentiated hematopoietic cells. The Philadelphia-negative MPNs 
include three main diseases: polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis 
(PMF)1.  The last decade has witnessed dramatic advances in our understanding of the molecular and cellular 
basis of excessive myeloproliferation, and this has led to the development and therapeutic use of novel 
targeted treatments, such as JAK inhibitors. More recently, we have begun to accumulate tantalising insights 
into the origins of these cancers, as well as the factors that drive later disease evolution.  
Here, we review our current understanding of the evolution of MPNs, from their origins to the 
emergence of disease and clinical progression. Our evolutionary narrative begins with a review of the 
molecular basis of myeloproliferation in an established neoplastic clone. We then address the factors that 
influence disease phenotypes in chronic phase and the basis for disease progression, following which we 
discuss what is known about how clonal populations of MPN cells might initially emerge. We conclude by 
considering the potential implications for clinical practice.  
 
Phenotypic driver mutations converge on JAK-STAT signalling 
The cardinal and mutually exclusive mutations in MPNs occur in JAK2, CALR or MPL, referred to 
herein as the ‘phenotypic drivers’ due to their role in driving the myeloproliferative phenotype.  In 2005, a 
single point mutation resulting in JAK2V617F was identified in the vast majority of patients with PV and half of 
those with ET or MF2–5. JAK2 is intimately associated with the cytoplasmic portions of receptors for key 
hematopoietic cytokines, such including erythropoietin (EPO), thrombopoietin (TPO) and granulocyte 
colony-stimulating-factor (G-CSF). Normal JAK2 functions to activate intracellular signalling pathways 
following ligand binding, however, JAK2V617F is rendered constitutively active. The mutation is understood to 
result in loss of the normal inhibitory function provided by the pseudokinase (JH2) domain upon the active 
(JH1) kinase domain - in this model, it is unclear whether the disrupted JH1/JH2 interface occurs within an 
individual JAK2 molecule, or between JAK2 dimers6.  The mutation may also result in direct activation of the 
JH1 domain via an SH2-JH2 linker7. Subsequent downstream activation of intracellular signalling occurs via 
 3 
Signal Transducer and Activator of Transcription (STAT) protein signalling, and to a lesser extent via mitogen-
activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signalling pathways, which together 
result in excessive myeloid cell proliferation and differentiation.  
Additional genetic aberrations that perturb JAK-STAT signalling are found in JAK2-unmutated MPNs. 
Mutations in the TPO receptor c-MPL at W515, and less commonly at S505, are found in 5-8% of patients 
with ET and MF8. These mutations are understood to result in conformation changes to the receptor that 
mimic the consequences of TPO binding, such that cytoplasmic JAK2 molecules are brought into close 
proximity conducive for activation, transphosphorylation and ligand-independent intracellular signalling9. As 
might be expected from the normal function of MPL, these mutations are associated with megakaryocyte 
proliferation, and disease phenotypes of ET and MF are recapitulated in murine models8.  
In 2013, mutations in calreticulin (CALR) were identified in the majority of JAK2- or MPL-unmutated 
patients with ET or MF10,11. CALR mutations are insertions or deletions affecting the terminal exon of the 
gene, which all result in a +1 base-pair shift to the amino-acid reading frame of the DNA sequence, such that 
the mutant protein acquires a novel C-terminus. The identification of such mutations was surprising since 
CALR was neither a cytokine receptor, nor a known participant in JAK-STAT signalling. Calreticulin is best 
known for its house-keeping function as a chaperone protein in the endoplasmic reticulum (ER), where it 
aids the appropriate folding of client protein molecules prior to their trafficking, either to the cell surface or 
for extracellular secretion12. However, knowledge that c-MPL is an ER client protein and that CALR mutations 
were associated exclusively with only ET or MF (hence, resembling MPL-mutated MPNs), suggested the 
possibility that mutant CALR somehow activates MPL. Consistent with this, mutant-CALR can induce an 
ET/MF phenotype in a variety of mouse models, but only in the presence of MPL13–17. The mechanism by 
which mutant CALR complexes with MPL to result in its constitutive activation remains unclear. The 
extracellular domain of MPL, along with both the N-terminal and mutant C-terminal of CALR appear 
necessary for this interaction, which may be facilitated by the newly acquired positive electrostatic charge 
within the C-terminus13,15. It is unclear why mutant CALR complexes preferentially with MPL and whether 
mutant-CALR mediated MPL activation occurs following transport from the ER to the cell surface, or if 
aberrant activation occurs intracellularly.  
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Uncommon variants in phenotypic drivers also lead to constitutive activation of JAK-STAT signalling, 
such as mutations in exon 12 of JAK2 and the recently identified non-canonical variant MPLS204P 18–20. 
Occasionally, other proteins that participate in JAK-STAT signalling (eg., SH2B3 and CBL) are also mutated in 
MPNs, although they are less frequently found as an isolated somatic mutation in patients21,22. Overall, 
excepting the ~10% of patients with MF or ET that have as yet undiscovered drivers of their disease10, 
aberrant activation of intracellular signalling via EPOR and/or MPL remains central to the development of 
the MPN phenotype, regardless of whether the phenotypic driver mutation is in JAK2, CALR or MPL (Figure 
1).  
 
Relationship between phenotypic drivers and clinical presentation 
CALR-mutated ET patients display a phenotype that is remarkably similar to those with MPL 
mutations. Both disease subgroups are characterised by isolated thrombocytosis and no gender bias at 
presentation23,24. However, CALR-mutated patients are significantly younger at presentation than both MPL-
mutated and JAK2-mutated counterparts. This is reminiscent of the disease characteristics of PV patients 
with JAK2V617F and JAK2exon12 mutations – those with the latter exhibit more marked erythrocytosis and 
present at a younger age18, differences which may reflect differential strengths of aberrant signalling via the 
EPO receptor (EPOR). By analogy, one can speculate that CALR mutations may result in higher levels of MPL 
signalling compared to those induced by heterozygous mutations in MPL or JAK2. Such a hypothesis accords 
with the observation that CALR-mutated ET patients have an increased risk of myelofibrotic 
transformations25, particularly since excessive signalling via the MPL receptor is associated with bone 
marrow fibrosis in transgenic mice26 and increased bone marrow reticulin is seen in ET patients with 
homozygous MPL mutations27. This would also be consistent with the observation that CALR mutations that 
result in a more extensive mutant C-terminus (Type 1, 52bp-deletion, L367fs*46) are more prevalent in 
patients with MF10,11, and result in a more severe phenotype with frequent MF transformation in a retroviral 
CALR-mutant mouse model14. 
In contrast to CALR or MPL, mutated JAK2
 
is pleiotropic and results in numerous MPN phenotypes 
also recapitulated in JAK2V617F mouse models28. A number of factors determine the phenotype that results 
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following a JAK2 mutation. First, specific types of JAK2 mutation, for example, V617I, V617F or mutations in 
exon 12, are associated with differing degrees of erythrocytosis versus thrombocytosis18,29. Recent data 
demonstrate that this may be due to the differential coupling of certain mutant JAK2 proteins with  cytokine 
receptors30. Exon 12 mutation K539I has been shown predominantly to bind EPOR, whereas JAK2V617F 
preferentially complexes with MPL30. Secondly, homozygosity for JAK2V617F is a key factor in determining the 
degree of erythrocytosis that subsequently develops, both in patient samples and animal models31–33. One 
can hypothesize that biallelic expression of JAK2V617F may be required for the mutant protein to 
preferentially complex with EPOR, although this is yet to be demonstrated. Whilst clones bearing 
homozygous JAK2V617F can be found as minor subclones in patients with ET, they are clonally dominant in 
patients with PV34. The factors that influence the degree of expansion of homozygous JAK2V617F clones are 
not fully understood, although the order in which JAK2V617F is acquired relative  to other somatic mutations 
has been shown to be important35. Thirdly, patient specific factors such as iron status, age, gender, 
coexistent beta-thalassaemia traits, and timing of presentation (relative to the course of the disease in a 
given patient) may all influence whether a patient harbouring JAK2V617F presents with significantly elevated 
red cell parameters and/or thrombocytosis at diagnosis36 (Figure 2).  
 
Genetic interactions influence disease presentation and progression 
Several additional genetic interactions shape the molecular, cellular and clinical consequences of 
phenotypic driver mutations in MPN.  
 
a. Germline predisposition. Constitutional variation that predisposes to MPNs can be classified into two 
groups: (i) common variants, prevalent in the population, that result in a small predisposition to MPN, and 
(ii) rare variants, often found in familial MPNs, that have a higher penetrance for disease. Well recognised 
examples of the former include the JAK2 46/1 haplotype, as well as single nucleotide polymorphisms (SNPs) 
in the gene TERT, that confer a ~1.5-3.5 fold increased odds of MPN37. Whilst up to 10% of patients are 
estimated to have additional affected family members, the germline loci responsible for predisposition in 
familial MPNs have been ascertained in only a handful of pedigrees38–41. Two broad mechanisms exist 
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through which germline variation may impact on MPN incidence. The observation that JAK2V617F is often 
found in cis with the 46/1 haplotype in heterozygous individuals, initially raised the possibility that this allele 
was predisposed to acquiring JAK2V617F. However, direct evidence to support such DNA hypermutability has, 
thus far, not been demonstrated. An alternative model contends that certain germline genetic backgrounds 
are more permissive for an MPN to emerge. Two recent studies provide evidence for the existence of such 
an interaction. (i) The association between ET and HBS1L-MYB SNP rs9376092 is understood to be through 
reduction in MYB expression, which is a recognised driver of thrombocytosis42. (ii) Germline duplication of 
ATG2B and GSKIP has been shown to enhance sensitivity of megakaryocyte progenitors to TPO, particularly 
in the presence of JAK2V617F, resulting in highly penetrant MPNs within certain families38. Given that many 
additional predisposition loci for MPNs have been recently identified across genes involved in cell 
senescence (TERT), JAK-STAT signalling (SH2B3), myeloid differentiation (GFI1B), DNA damage and repair 
(ATM, CHEK2) and epigenetic regulation (TET2), suggests that the germline genetic background of an 
individual may influence diverse biological cellular functions to accentuate the molecular and cellular 
consequences of nascent MPN clones following their acquisition of phenotypic driver mutations43.  
 
(ii) Additional somatic mutations in MPNs. Approximately one third of patients with MPN have additional 
mutations in known drivers of myeloid malignancies. These mutations alter DNA methylation (DNMT3A, 
TET2, IDH1/2), chromatin modifications (ASXL1, EZH2, IDH1/2), mRNA splicing (U2AF1, SF3B1, SRSF2, ZRSR2), 
and DNA repair (TP53)10. The presence of certain mutations, such as in ASXL1, SRSF2, IDH1/2 and EZH2 in 
patients with MF are associated with an increased risk of leukemic transformation and/or reduced survival44. 
Investigation of the biological effects of these additional mutations reveal common molecular perturbations, 
as illustrated in the examples below.  
Methylation of cytosines at CpG sites is a mechanism through which information establishing stem 
cell and differentiation states is retained by cells followed cell division. DNMT3A is a de novo 
methyltransferase, and TET2, a member of the TET family of proteins, hydroxymethylates methylcytosines, 
which may be viewed simplistically as a process of demethylation. Mutations in both genes are prevalent 
across MPNs, understood to be loss-of-function (or dominant-negative effects for DNMT3AR882H 45),  and 
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result in a hematopoietic stem cell (HSC) advantage in murine models46–49. The similarities in loss-of-function 
consequences despite seemingly opposing functions has recently been reconciled by work demonstrating 
that DNMT3A cooperates with TET2 to (i) promote the activity of enhancers important in ensuring stem cell 
fitness through the maintenance of high levels of DNA hydroxymethylation at enhancer centres50; and (ii) 
repress key lineage-specific transcription factors that promote differentiation in hematopoiesis51. Mutations 
in IDH1/2 also affect DNA methylation via the generation of 2-hydroxyglutarate (2HG) that competitively 
inhibits alpha-KG dependent DNA-hydroxylases, such as TET2 and Jumonji family histone-demethylases52,53. 
Mutant IDH1 has also been linked to increased DNA damage via downregulation of the DNA damage sensor 
ATM54. Knock-in mice for IDH1R132H suffer expansion of HSPCs, extramedullary hematopoiesis and anemia55, 
in keeping with this mutation being found in advanced phases of MPN. 
Perturbation of polycomb repressor complex 2 (PRC2) is another pathogenic mechanism prevalent 
in MF. EZH2, the enzymatically active subunit of PRC2, compacts chromatin and represses gene transcription 
via histone H3 (H3K27) trimethylation at lysine 27 (H3K27). In myeloid malignancies, EZH2 loss-of-function 
mutations lead to derepression of several target genes, such as the Hox gene family that enhances HSC self-
renewal, and Lin28b/ Hmga2 that promote fibrosis and reduce erythropoiesis in a JAK2V617F context56–58. 
Loss of EZH2 can also be a consequence of other genetic perturbations, such as loss of heterozygosity at 
chromosome 7q, as well as mutations in spliceosome components U2AF1 and SRSF259,60. Mutations in ASXL1 
are present in up to a quarter of patients with MF, and also leads to reduced PRC2 recruitment, although 
other additional pathogenic effects have been reported 61–63.  
 
(iii) Order of mutation acquisition. Akin to other cancers, MPNs are clonally heterogeneous reflecting the 
ongoing interplay between somatic mutation, cellular adaptation to the changing microenvironment and 
selection of tumor subclones. The sequence of acquisition of somatic mutations can be inferred from the 
genotypes of detectable subclones. For instance, if some tumor cells have JAK2V617F, and others from the 
same patient bear JAK2V617F with an additional somatic mutation, then it indicates that JAK2V617F came first. 
By genotyping individual hematopoietic colonies it has been shown that the order of acquisition of JAK2V617F, 
relative to mutations in TET2 or DNMT3A, influences subclonal composition within hematopoietic 
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stem/progenitor cells (HSPC) and mature cell compartments, disease presentation and clinical outcome35,64. 
In JAK2-first patients, the HSPC compartment is dominated by double-mutant cells, and such patients 
present at a younger age, often with PV35. Conversely, in TET2-first patients, the HSPC compartment is 
dominated by single-mutant cells, and such patients present at an older age, usually with ET. Studies of 
mutation order have also revealed that DNMT3A mutations, often thought to be early events, frequently 
occur after an initial JAK2 mutation. This situation is difficult to detect in the absence of clonal assays since 
only small numbers of JAK2 single-mutant colonies may be present, probably reflecting their out-
competition by double-mutant clones elderly. At least 3 mechanisms, not mutually exclusive, may underlie 
these observations. (i) The first mutation may alter a cell’s response to the second mutation. Thus, the 
transcriptional response to TET2 is altered by the presence of a prior JAK2V617F mutation35. (ii) The first 
mutation may alter HSC differentiation and give rise to altered target cell populations in which the second 
mutation can arise. (iii) The first mutation may alter the number and function of mature progeny and thus 
affect the bone marrow microenvironment. Further studies are required to address which mechanisms are 
most important in driving the phenotypic differences in patients with different temporal patterns of 
mutation acquisition, and whether phenotype in chronic phase, or disease progression, are influenced by 
the order of acquisition of other pairs of common mutations. 
 
Disease initiation and clonal outgrowth in MPNs 
The conventional view of hematopoiesis envisions a self-renewing pool of long-term repopulating HSCs 
producing terminally differentiated cells via a series of intermediates. However, recent data from mice 
suggest that steady state hematopoiesis does not routinely rely on HSCs, but predominantly reflects the 
successive recruitment of thousands of transiently active progenitors65,66. Furthermore, there is now 
compelling evidence for heterogeneity in the differentiation potential of individual cells within the HSC 
compartment in mice67–69.  
Direct evidence for a clonal stem-cell origin of MPNs came 40 years ago when Adamson and colleagues 
demonstrated that females with PV who were heterozygous for two glucose-6-phosphate dehydrogenase 
alleles expressed only one allele in their blood cells70. Both JAK2V617F and CALR-mutated cells are readily 
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detectable in immunophenotypically defined HSPCs and across all myeloid lineages, confirming that these 
mutations arise in cells close to the apex of the hematopoietic hierarchy10,71. It is tempting to speculate that 
following the acquisition of a driver mutation, platelet-biased HSCs might be particularly prone to giving rise 
to an MPN, but direct evidence for this is currently lacking. In some studies but not others, JAK2V617F has 
been found in the lymphoid compartments of MPN patients raising the possibility that HSCs with differing 
degrees of lymphoid potential are targets of somatic mutation in different patients72–76. However, 
alternative explanations include the presence of other somatic mutations, and the long-lived nature of 
mature lymphocytes which means it may be many years before an HSC mutation becomes detectable in 
lymphocyte populations. Regardless of the uncertainty over the precise nature of the cell(s)-of-origin, for 
MPNs to emerge requires that (i) these cells acquire phenotypic driver mutations, and (ii) this results in 
persistent and significant clonal outgrowth.  
 
(i) Acquisition of mutations in hematopoiesis. Human cells accumulate somatic mutations throughout their 
life time as a result of cell-intrinsic mutational processes and exposure to external mutagens. The 
accumulated DNA changes in a single cell can be viewed as a ‘barcode’ that can then be used to estimate 
tissue-specific mutation rates, trace the cell’s developmental origins, and understand the nature of DNA 
damaging processes. Under normal circumstances, these genetic changes are unique to individual cells, 
making their study possible only through single-cell interrogation techniques. However, the clonal expansion 
of tumors renders these aberrations detectable in bulk tissue. Study of these mutation spectra in cancer 
reveal many mutational patterns, so called ‘mutation signatures’, that in turn inform us of the biological 
processes that drive mutation acquisition in normal tissues as well as in cancer77,78. 
 Compared to solid tumors, hematopoietic malignancies are relatively mutation sparse. A key study 
by Ley and colleagues demonstrated that the mutation rate in acute myeloid leukemia (AML) was not 
elevated relative to age-matched hematopoietic progenitors from healthy individuals, suggesting that most 
mutations present in AML reflect those acquired prior to oncogenic transformation79. Two mutational 
patterns have been recognised to contribute to background mutation acquisition in myeloid cells. The first 
('signature 1’) is understood to be the consequence of spontaneous deamination of methylcytosines, which 
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results in an age-associated genome-wide accumulation of C>T transition mutations at CpG 
dinucleotides77,79. The second pattern of mutations (signature 5) exhibits various nucleotide changes at low 
frequency, but with a small bias towards T>C mutations occurring on the transcribed DNA strand77. The 
aetiology of this mutation signature is not currently known. Both mutational signatures are observed 
ubiquitously across somatic tissues as well as in the germline80.  
 Whether these background mutational processes are sufficient to explain the acquisition of specific 
oncogenic mutations remains the subject of ongoing research. Two observations suggest that the frequency 
of acquisition of oncogenic drivers may occur at higher rates than conventionally thought. First, some 
patients with MPN have been shown to harbour multiple oncogenic driver mutations in ancestrally unrelated 
clones, suggesting that these mutations can arise multiple independent times in the same individual81,82. 
Second, in a recent study of familial MPN, two-thirds of carriers of a germline duplication (involving ATG2B 
and GSKIP) developed an MPN harbouring a somatic mutation in JAK2, CALR or MPL. The germline 
duplication enhanced the outgrowth of mutant cells, and there was no without co-existent evidence of 
hypermutability that might otherwise have increased mutation acquisition in these patients38. Together 
these data suggest that acquisition of phenotypic driver mutations in cells capable of initiating MPNs might 
be relatively frequent, but that clones either remain small (and thus undetected in analyses of cell 
populations), or do not normally survive, unless additional conditions facilitate their clonal expansion.  
 
(ii) Factors influencing clonal outgrowth of cells with phenotypic driver mutations. Approximately half of 
patients with a JAK2V617F-mutated MPN in chronic phase lack additional somatic mutations in oncogenic 
drivers. However, studies in mice suggest that whilst JAK2V617F is capable of driving an MPN phenotype, it 
may be less able to initiate clonal expansion in an individual HSC. Three different knock-in mouse models 
have shown that JAK2V617F-HSCs are either no better, or they are less adept than wildtype HSCs in initiating 
clonal expansion, as assayed by competitive repopulation transplantation assays28. Furthermore, 
transplantation of single JAK2V617F-HSCs into recipient mice only rarely results in an MPN phenotype83. 
Therefore, additional factors may be required for an initiating JAK2 mutation to result in an expanded 
mutant clone. These may include interaction with the constitutional genetic background of a patient, or a 
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physiological stochastic expansion of individual HSCs that is independent of the driver mutation. Moreover, 
there is increasing evidence that ageing and the bone marrow microenvironment may play important roles.  
 Ageing is a strong risk factor for MPN. Recent studies demonstrate that with increasing age clonal 
hematopoietic expansions occur in the absence of overt haematological disease84–87. Mutations leading to 
clonal hematopoiesis (CH) commonly involve DNMT3A, TET2, ASXL1, PPM1D, but also JAK2V617F. Interesting, 
mutations in CALR have not yet been reported in CH. This may be a reflection of the inherent challenges in 
detecting such mutations from standard exome sequencing due to poor sequencing coverage and alignment 
efficiency over the mutated region. However, it also raises the possibility that CALR mutations have a higher 
penetrance for the development of overt disease. Several observations suggest that CH is not simply a 
reflection of the increased risk of mutation acquisition with age, but that ageing itself favors clonal expansion. 
First, CH is rare under the age of 40, but increases exponentially in the elderly; a pattern inconsistent with a 
linear rate of somatic mutation accumulation over time79. Secondly, some mutations (eg SF3B1) are only 
associated with CH more advanced decades of life87; it would be unlikely that specific mutations are acquired 
at different rates in different age groups. Thirdly, no known oncogenic drivers can be identified from analysis 
of whole-exome or whole-genome sequencing in up to half of individuals with CH, suggesting that oncogene-
independent mechanisms such as clonal drift or reduced bone marrow genetic diversity, can lead to clonal 
expansion86,88. It is recognised that HSCs undergo a wide range of age-related biochemical and functional 
changes and it seems plausible that some of these may favor the outgrowth of cells that acquire a driver 
mutation89. Moreover, both cell-intrinsic and environmental influences are likely to play a role.  
 Several lines of evidence point to the importance of environmental effects. Medical interventions, 
immune dysregulation and inflammation have all been shown to alter selective pressures for mutant clones 
within the bone marrow. In TP53-mutated therapy-related MDS, TP53-mutated cells have been 
demonstrated to pre-exist at low levels prior to any exposure to therapy, but only outgrow in the context of 
post-chemotherapy bone marrow90. Furthermore, CH is prevalent in the bone marrow of patients with 
aplastic anemia, where one can envisage that immune-mediated destruction of normal bone marrow cells 
favors selection for clones more adept at evading cell death, such as those bearing PIG-A mutations, deletion 
of the major histocompatibility locus on chr 6p or mutations in TP53-inhibitor PPM1D91. There is also 
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increasing evidence that inflammation has a key role in promoting MPN initiation and influencing disease 
evolution. The secretion of pro-inflammatory cytokines by bone marrow stromal cells, such as 
interleukin(IL)-6, IL-33, fibroblast growth factor (FGF), C-X-C motif ligand 10 (CXCL10), IL-33 and tumor 
necrosis factor alpha (TNFα), have been shown to preferentially promote the expansion of JAK2V617F-
mutated clones92–94. Furthermore, elevated levels of NFE-2 (itself induced by inflammatory cytokine IL-
1beta), has been shown to drive MPN proliferation and progression through modulation of inflammatory 
cascades including elevated IL-8 expression95,96. Overall, it remains unclear exactly how a single phenotypic 
driver mutation initiates a clonal expansion that will evolve into an overt MPN, but current evidence suggests 
that the constitutional genetic background, ageing process, and tumor microenvironment are key factors, 
with each exerting cell-intrinsic and environmental effects (Figure 3).  
 
Clinical implications and future directions 
The JAK inhibitor Ruxolitinib has been a valuable addition to the therapeutic armamentarium for 
MPNs, in particular for patients with MF suffering from splenomegaly and/or disease related symptoms97,98. 
However, allogeneic stem cell transplantation (ASCT) still remains the only potentially curative treatment 
for MPNs, an approach limited by age-related comorbidities and high treatment related mortality. 
Demonstrable disease modifying activity for conventional therapeutic agents is lacking. Ruxolitinib and 
Interferon alpha have been associated with reductions in allele-burdens of phenotypic drivers mutations in 
some cases, but molecular response is variable and unpredictable. Amongst the multitude of novel agents 
tested in clinical trials, many have shown clinical responses but only in a minority of patients, or there are 
dose-limiting toxicities99. Patient heterogeneity may be a key factor contributing to the lack of demonstrable 
clinical efficacy for many agents. Therefore, a major challenge is how we use our emerging understanding 
of the pathogenetic basis of MPNs to identify groups of patients with shared disease biology and clinical 
outcome, such that both existing therapies, as well as novel agents, can be better targeted to specific patient 
groups. Novel paradigms for both disease classification and predictions of clinical outcome may be needed 
to meet this goal.  
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The 2016 revision to the World Health Organization classification of MPNs retains the traditional 
distinction between PV, ET and MF, and distinguishes between pre-fibrotic and fibrotic MF1. However, such 
a conceptual schema has significant weaknesses. First, there is a fundamental challenge associated with 
defining diseases as discrete entities on the basis of continuous variables, such as hemoglobin level or 
amount of bone marrow fibrosis100. Secondly, there is emphasis on the identification of cytological nuances 
(especially megakaryocyte morphology) that are subjective in their interpretation and which have been 
shown to have poor inter-observer consensus101–103. Thirdly, despite the importance of somatic mutations, 
there remains substantial molecular overlap between, and heterogeneity within, MPN categories10. 
Furthermore, there is significant overlap between the spectrum of mutations found in MPN and 
myelodysplasia (MDS), and it is unclear whether patients with MF who lack mutations in JAK2, CALR or MPL, 
have disease biology more akin to MDS than MPN. Accurate classification is critical as it predetermines the 
therapeutic strategy employed by clinicians. Therefore, there is a rationale for large-scale sequencing studies 
that incorporate patients with MPN, MDS and related myeloid conditions, combined with clinical and 
laboratory parameters, in order to provide a more biological basis for the way we classify these disorders in 
the future.  
 Another major goal for the future is to identify, at an early stage, those patients at risk of a poor 
outcome. The International Prognostic Scoring System (IPSS) 104 has been valuable when considering the 
timing of ASCT in patients with MF. However, there are several ongoing challenges. First, current prognostic 
scoring systems apply to patients with MF, and there are no predictive models for use in patient with chronic 
phase MPN. Secondly, multiple scoring systems are required for patients with MF, depending on whether 
risk stratification is performed at diagnosis or later105, whether MF is primary or post-ET/post-PV106–108, and 
the age of the patient105. Thirdly, both the IPSS and Dynamic IPSS (DIPSS) rely on potentially subjective scores 
for the presence or absence of constitutional symptoms. Recently, patient age together with JAK2, CALR and 
MPL status, have been used to build a simple yet objective predictive model for patients with MF109. 
However, such a model does not take into account the presence of additional somatic mutations that 
strongly associate with outcome110. Comprehensive sequencing of patients, combined with clinical 
parameters and longitudinal follow up, are now required in order to elucidate how the various genetic and 
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non-genetic factors contribute to the different possible outcomes for MPN patients. Such a ‘knowledge bank’ 
approach has been developed in AML111, and has the potential to deliver a universal and clinically relevant 
model for predicting outcome for all patients with MPN.  
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Figure 1. Mutations in JAK2, CALR and MPL drive excessive myeloproliferation via constitutively active 
signalling downstream of JAK2. JAK2 associates with the cytoplasmic portion of a variety of receptors, such 
as those for erythropoietin (EPOR), thrombopoietin (MPL) and granulocyte/macrophage colony-
stimulating factor (G-CSFR). JAK2 is also activated in response to additional cytokines (eg., growth 
hormone and interleukin-5) (not shown). Left panel. Mutant JAK2, shown in red, is constitutively active and 
leads to variable levels of erythroid, megakaryocytic and to a lesser degree granulocytic proliferation and 
differentiation. It is unclear whether mutant JAK2 dimerises with mutant or wildtype JAK2 with respect to 
the individual receptors. Right panel. Mutations in CALR and MPL result in aberrant activation of signalling 
downstream of the MPL receptor. Mutant CALR complexes with MPL in the endoplasmic reticulum (ER). 
Both mutations in CALR and MPL result in receptor dimerization and activation of JAK2. STATs, Signal 
Transducer and Activator of Transcription; MAPK/ERK, mitogen-activated protein kinases/extracellular 
signal-regulated kinases; PI3/AKT, phosphoinositide 3-kinase/serine/threonine kinase Akt.  
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Figure 2. Clinical presentation in chronic phase and relationship to phenotypic driver mutation. PV and ET are 
modelled as a disease spectrum along a biological continuum where different genetic lesions skew the 
clinical phenotype from that of thrombocytosis to that of additional erythrocytosis (+/- leucocytosis). CALR 
mutations result in excessive MPL signalling, in a manner similar to that resulting from MPL mutations. JAK2 
mutations signal downstream of multiple cell surface receptors including MPL, and are thus associated with 
thrombocytosis but also erythrocytosis and leucocytosis. The exact nature of the phenotypic driver mutation, 
germline genetic background and additional somatic mutations influence disease phenotype. *In the 
context of JAK2V617F, specific factors modulate the balance between erythrocytosis and thrombocytosis, such 
as gender, mutation homozygosity, and patient specific factors such as erythropoietin (EPO) levels, renal 
function and iron status.  
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Figure 3. From origins to outcomes. Different evolutionary paths to MPN and disease progression in four 
patients, each with their unique genetic background (green, grey, red, blue). In the first patient (green), a 
phenotypic driver mutation is acquired in a hematopoietic stem cell (HSC) results in clonal expansion and 
the emergence of an MPN phenotype as a consequence of favourable cell-intrinsic and/or environmental 
factors. The MPN in this context has no additional oncogenic driver mutations, as is common for patients in 
chronic phase. Additional driver mutations, such as those that perturb polycomb repressor 2 function (EZH2, 
ASXL1 mutations), spliceosome components (SRSF2, SF3B1, U2AF1), or DNA damage repair (TP53), can lead 
to cells gaining a further clonal advantage and disease progression. In the second patient (grey), the cell-
 18 
intrinsic and/or environmental context is not favourable, and a cell acquiring a phenotypic driver mutation 
does not have a clonal advantage relative to competing normal cells. In some circumstances, a phenotypic 
driver mutation may be insufficient to result in abnormal blood counts and an overt MPN but can instead 
result in a clonal expansion. Additional mutations or cell-extrinsic changes may be required to result in 
emergence of disease (patient in red). Finally, in some patients, phenotypic driver mutations may not be the 
first event. Clonal hematopoiesis as a result of mutations in, for example, TET2, DNMT3A, ASXL1 may be the 
required backdrop for a phenotypic driver mutation to result in an overt MPN (patient in blue). 
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